Betamethasone with neomycin
Brand names: Betnesol-N, Vista-Methasone N
A topical fixed-combination of the potent corticosteroid betamethasone with the aminoglycoside antibacterial neomycin, used for inflammatory skin conditions complicated by susceptible bacterial infection.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Betamethasone reduces local inflammation and immune activity, while neomycin binds the bacterial ribosome to inhibit protein synthesis against a range of Gram-negative and some Gram-positive organisms.
Prescribing in practice
- Topical neomycin is a common cause of contact allergic sensitisation, and absorption from large or broken areas carries a risk of oto- and nephrotoxicity, so application should be limited in area and duration.
- Avoid prolonged potent-steroid use on the face and flexures and avoid occlusion.
- Do not apply over extensive or denuded skin where systemic aminoglycoside absorption could occur.
Monitoring
Review the response over a short course and stop if there is no improvement or if signs of contact allergy (worsening eczema, spreading redness) appear.
Counselling the patient
- Stop and seek advice if the treated skin becomes more red, itchy or irritated, which may signal an allergy to the antibiotic.
- Apply a thin film to the affected area and avoid covering with airtight dressings.
Evidence & guidelines
Cautions on neomycin sensitisation and systemic aminoglycoside toxicity follow the SPC and standard dermatology references.
Reference: NICE CKS Otitis externa; NICE NG198; ENT UK; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD